Article

ThromboGenics to launch ocriplasmin in United States

ThromboGenics NV has confirmed a date of Jan. 14 for the U.S. launch of ocriplasmin intravitreal injection (Jetrea).

 

Leuven, Belgium-ThromboGenics NV has confirmed a date of Jan. 14 for the U.S. launch of ocriplasmin intravitreal injection (Jetrea).

The product is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA). The U.S. price for a single-use glass vial is set at $3,950.

The product represents a paradigm shift and for the first time offers a pharmacological treatment option to patients suffering with symptomatic VMA. The FDA approved Jetrea in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA.

ThromboGenics will be making a presentation concerning the launch on Wednesday, Jan. 9 during the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.